Akebia Therapeutics (AKBA) Reports In-Line Q2 EPS

Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $43.65 million versus the consensus estimate of $49.47 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Nvidia launches BioNeMo Agent Toolkit for life sciences AI agents